Trial Profile

Study of Nasal Insulin to Fight Forgetfulness - Combination Intranasal Insulin and Empagliflozin Trial

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 30 Dec 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Empagliflozin (Primary) ; Insulin (Primary)
Indications Acute heart failure; Cardiovascular disorders; Chronic heart failure; Gestational diabetes; Heart failure; Insulin resistance; Renal failure; Type 1 diabetes mellitus; Type 2 diabetes mellitus
Focus Adverse reactions

Most Recent Events

01 Oct 2024 Status changed from recruiting to completed.
01 Aug 2024 Complete trial results including effects on CSF and blood AD biomarkers will be available in Q3-2024.
10 Nov 2021 Planned End Date changed from 1 Nov 2028 to 1 Oct 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com